Cargando…

Prognostic value of tumor mutation burden (TMB) and INDEL burden (IDB) in cancer: current view and clinical applications

Detalles Bibliográficos
Autores principales:	Saeed, Anwaar, Salem, Mohamed E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7290524/ https://www.ncbi.nlm.nih.gov/pubmed/32566602 http://dx.doi.org/10.21037/atm-2020-75

Ejemplares similares

The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients
por: Cui, Shengjin, et al.
Publicado: (2023)

Open the Technical Black Box of Tumor Mutational Burden (TMB): Factors Affecting Harmonization and Standardization of Panel-Based TMB
por: Sung, Meng-Ta, et al.
Publicado: (2022)

ecTMB: a robust method to estimate and classify tumor mutational burden
por: Yao, Lijing, et al.
Publicado: (2020)

Data collection and analysis on the burden of injuries: Lessons learned from the IDB network
por: Bauer, R, et al.
Publicado: (2023)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Tumor mutation burden (TMB)-associated signature constructed to predict survival of lung squamous cell carcinoma patients
por: Yan, Dan, et al.
Publicado: (2021)

Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing
por: Yu, Yongfeng, et al.
Publicado: (2021)

Predictive value of tumor mutation burden (TMB) with targeted next-generation sequencing in immunocheckpoint inhibitors for non-small cell lung cancer (NSCLC)
por: Ma, Xiaoting, et al.
Publicado: (2021)

Measuring Tumor Mutational Burden (TMB) in Plasma from mCRPC Patients Using Two Commercial NGS Assays
por: Qiu, Ping, et al.
Publicado: (2019)

Radiomic assessment as a method for predicting tumor mutation burden (TMB) of bladder cancer patients: a feasibility study
por: Tang, Xin, et al.
Publicado: (2021)

PathwayTMB: A pathway-based tumor mutational burden analysis method for predicting the clinical outcome of cancer immunotherapy
por: Li, Xiangmei, et al.
Publicado: (2023)

Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkers
por: Palmeri, M., et al.
Publicado: (2021)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

The Greater Value of the CONSORT Statement Guidelines: Guideposts for Designing and Reporting all TMB Research
por: Porcino, Antony J.
Publicado: (2012)

Assessing the Burden and Prognostic Value of Cough in Idiopathic Pulmonary Fibrosis
por: Johnston, Janet, et al.
Publicado: (2023)

Association Between Tumor Mutation Burden (TMB) and Outcomes of Cancer Patients Treated With PD-1/PD-L1 Inhibitions: A Meta-Analysis
por: Zhu, Jiaxin, et al.
Publicado: (2019)

The Predictive Efficacy of Tumor Mutation Burden (TMB) on Nonsmall Cell Lung Cancer Treated by Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Nan, Zhang, et al.
Publicado: (2021)

Prognostic value of tumor burden in nasopharyngeal carcinoma
por: Chen, Chuanben, et al.
Publicado: (2018)

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels
por: Ramos-Paradas, Javier, et al.
Publicado: (2021)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Correlations Between Tumor Mutation Burden and Immunocyte Infiltration and Their Prognostic Value in Colon Cancer
por: Zhou, Zhangjian, et al.
Publicado: (2021)

Multi-omics analysis reveals prognostic value of tumor mutation burden in hepatocellular carcinoma
por: Xu, Qianhui, et al.
Publicado: (2021)

An Identity-Based (IDB) Broadcast Encryption Scheme with Personalized Messages (BEPM)
por: Xu, Ke, et al.
Publicado: (2015)

Tumor mutational burden and immune signatures interplay in renal cell carcinoma
por: Yakirevich, Evgeny, et al.
Publicado: (2020)

The relationship between different subtypes of KRAS and PD-L1 & tumor mutation burden (TMB) based on next-generation sequencing (NGS) detection in Chinese lung cancer patients
por: Yang, Ying, et al.
Publicado: (2022)

Prognostic Value of Tumor Mutational Burden Related to Immune Infiltration in Cervical Squamous Cell Carcinoma
por: Wen, Fang, et al.
Publicado: (2021)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

The prognostic value of tumor mutational burden and immune cell infiltration in esophageal cancer patients with or without radiotherapy
por: Yuan, Cheng, et al.
Publicado: (2020)

Prognostic value of tumor mutation burden in patients with advanced gastric cancer receiving first-line chemotherapy
por: Duan, Xiao-Peng, et al.
Publicado: (2023)

Exploring the prognostic function of TMB-related prognostic signature in patients with colon cancer
por: Zhao, Yan, et al.
Publicado: (2023)

Can tumor mutational burden determine the most effective treatment for lung cancer patients?
por: Wang, Shixiang, et al.
Publicado: (2020)

Arena-Idb: a platform to build human non-coding RNA interaction networks
por: Bonnici, Vincenzo, et al.
Publicado: (2018)

PlantMWpIDB: a database for the molecular weight and isoelectric points of the plant proteomes
por: Mohanta, Tapan Kumar, et al.
Publicado: (2022)

Assessing tumor heterogeneity: integrating tissue and circulating tumor DNA (ctDNA) analysis in the era of immuno-oncology - blood TMB is not the same as tissue TMB
por: Fridland, Stanislav, et al.
Publicado: (2021)

TERT mutations correlate with higher TMB value and unique tumor microenvironment and may be a potential biomarker for anti‐CTLA4 treatment
por: Li, Huahua, et al.
Publicado: (2020)

Tumor Mutational Burden in Breast Cancer: Current Evidence, Challenges, and Opportunities
por: Barroso-Sousa, Romualdo, et al.
Publicado: (2023)

Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery
por: Moreira, A., et al.
Publicado: (2021)

The prognostic value of tumor mutational burden related 6-gene-based Risk Score in laryngeal cancer patients
por: Yang, Dong, et al.
Publicado: (2022)

IDbSV: An Open-Access Repository for Monitoring SARS-CoV-2 Variations and Evolution
por: Essabbar, Abdelmounim, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8u33vvlbfp6d7os5qd91enn03e